Clal Biotechnology Industries Ltd. announced the appointment of Julian Adams Ph.D. as president and chief science officer. Dr. Adams has more than 30 years of experience in drug discovery and development with a strong focus on oncology. Until recently, he served as Infinity Pharmaceuticals president R&D. Prior to joining Infinity, Dr. Adams was SVP drug discovery and development at Millennium Pharmaceuticals, where he headed multiple global drug discovery programs, including the Velcade® (bortezomib) program. Dr. Adams also held senior positions in R&D at LeukoSite (acquired by Millennium) and at ProScript, as well as in Boehringer Ingelheim, where he was credited with the discovery of Viramune® (nevirapine) for HIV.